~~<i id='1C0236FF24'><strike id='1C0236FF24'><tt id='1C0236FF24'><pre id='1C0236FF24'></pre></tt></strike></i>~~

Home» knowledge» Wikipedia

Wikipedia

author：Wikipedia 2025-09-30 06:27:58 Page View：7

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Lung cancer screening guidelines updated for cigarette smokers
Next article： Heart attack and stroke risk calculators need revising

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Travis Kelce and the trap of celebrity vaccine endorsements

Illustration:STAT;ScreencaptureOncethedomainofagingTVstars,hawkinghealthproductsfromvitaminstodiabet

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

After Sarepta trial failure, Duchenne families brace for more debate

KristofferTripplaar/SipaviaAPTohearSareptaCEODougIngramtellit,theresultsMondayafternoonfromalargetri